Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
The proteasome has emerged as a novel target for antineoplastic treatment of hematological malignancies and solid tumors, including those of the central nervous system. To identify cell death pathways activated in response to inhibition of the proteasome system in cancer cells, we treated human SH-SY5Y neuroblastoma cells with the selective proteasome inhibitor (PI) epoxomicin (Epoxo). Prolonged exposure to Epoxo was associated with increased levels of poly-ubiquitinylated proteins and p53, release of cytochrome c from the mitochondria, and activation of caspases. Analysis of global gene expression using high-density oligonucleotide microarrays revealed that Epoxo triggered transcriptional activation of the two Bcl-2-homology domain-3-only (BH3-only) genes p53 upregulated modulator of apoptosis (PUMA) and Bim. Subsequent studies in PUMA- and Bim-deficient cells indicated that Epoxo-induced caspase activation and apoptosis was predominantly PUMA-dependent. Further characterization of the transcriptional response to Epoxo in HCT116 human colon cancer cells demonstrated that PUMA induction was p53-dependent; with deficiency in either p53 or PUMA significantly protected HCT116 cells against Epoxo-induced apoptosis. Our data suggest that p53 activation and the transcriptional induction of its target gene PUMA play an important role in the sensitivity of cancer cells to apoptosis induced by proteasome inhibition, and imply that antineoplastic therapies with PIs might be especially useful in cancers with functional p53.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“As proteasome inhibitors induce apoptosis in several cell lines [26–28]”
From PSMC5 insufficiency and P320R mutation impair proteasome function (2024) · cites this paper as [27]
Citations
Cites
Phosphorylation meets ubiquitination: the control of NF-κB activity
Karin, M., & Ben-Neriah, Y. (2000) · Annual Review of Immunology · doi:10.1146/annurev.immunol.18.1.621 · Cited by 4,766
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · cited 1×
“NF-kB is constitutively activated in many cancer cells and is associated with cancer development and progression (Karin, 2006).”
BackgroundA Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632 · cited 1×
“Indeed, clinical efficiency of Bortezomib (PS-341/Velcade), a reversible PI has recently been observed in multiple myeloma patients (Richardson et al., 2003).”
BackgroundPUMA, a Novel Proapoptotic Gene, Is Induced by p53
Nakano, K., & Vousden, K. H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00214-3 · Cited by 2,315 · cited 2×
“PUMA has been identified as a key mediator of the p53dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001).”
BackgroundPalombella, V. J., Rando, O. J., Goldberg, A. L., & Maniatis, T. (1994) · Cell · doi:10.1016/s0092-8674(94)90482-0 · Cited by 2,096 · cited 1×
“Indeed, the activity of several transcription factors, including p53 and nuclear factor kappa B (NF-kB) (Chowdary et al., 1994; Palombella et al., 1994), are known to be modulated by proteasome activity.”
Backgroundc-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism
Dang, C. V. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.1.1 · Cited by 1,715 · cited 1×
“The most prominently downregulated genes after proteasome inhibition were members of the c-Myc family of transcription factors which control expression of genes involved in cell growth and metabolism (Dang, 1999).”
BackgroundBouillet, P., Metcalf, D., Huang, D. C. S., Tarlinton, D. M., Kay, T. W. H., Köntgen, F., Adams, J. M., & Strasser, A. (1999) · Science · doi:10.1126/science.286.5445.1735 · Cited by 1,504 · cited 1×
“The generation of the PUMA / and Bim / mice have been described previously (Bouillet et al., 1999; Villunger et al., 2003a).”
MethodSelf-citationp53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa
Villunger, A., Michalak, E. M., Coultas, L., Müllauer, F., Böck, G., Ausserlechner, M. J., Adams, J. M., & Strasser, A. (2003) · Science · doi:10.1126/science.1090072 · Cited by 1,327 · cited 3×
“Oncogene imbalance between proapoptotic and antiapoptotic Bcl-2 proteins resulting in the release of cytochrome c and apoptosis (Villunger et al., 2003a; Willis and Adams, 2005).”
BackgroundMethodSelf-citationPUMA Induces the Rapid Apoptosis of Colorectal Cancer Cells
Yu, J., Zhang, L., Hwang, P. M., Kinzler, K. W., & Vogelstein, B. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00213-1 · Cited by 1,280 · cited 3×
“PUMA has been identified as a key mediator of the p53dependent apoptotic response (Nakano and Vousden, 2001; Yu et al., 2001).”
BackgroundThe proteasome: a suitable antineoplastic target
Adams, J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1361 · Cited by 1,201 · cited 1×
“Several key regulatory proteins involved in cell proliferation and differentiation are regulated by proteasome-mediated proteolysis resulting in the activation or inhibition of specific cell signaling pathways (”
Background
Research works printed but not linked: 1
- Adams J . (2004b). The proteasome: a suitable antineoplastic target. Nat Rev Cancer 4: 349–360. · DOI · Paper page
Cited by
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
“In tumor cells with wild-type p53, however, proteasome inhibitors can instead act by driving p53-dependent expression of Puma (Concannon et al., 2006).”
BackgroundPUMA, a potent killer with or without p53
Yu, J., & Zhang, L. (2008) · Oncogene · doi:10.1038/onc.2009.45 · Cited by 554
“, 2005), and cancer cell death induced by the proteasome inhibitors MG-132, bortezomib and epoxomicin (Concannon et al., 2007; Ding et al., 2007), and by the monoflavonoid wogonin (Lee et al.”
An Epstein-Barr virus–encoded microRNA targets PUMA to promote host cell survival
Choy, E. Y.-W., Siu, K.-L., Kok, K.-H., Lung, R. W.-M., Tsang, C. M., To, K.-F., Kwong, D. L.-W., Tsao, S. W., & Jin, D.-Y. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20072581 · Cited by 462
Bcl-2 family on guard at the ER
Szegezdi, E., MacDonald, D. C., Ní Chonghaile, T., Gupta, S., & Samali, A. (2009) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00612.2008 · Cited by 241
“Puma has also been shown to be required for the initiation of apoptosis in neuronal cells triggered by the abnormal accumulation of malformed proteins associated with several neurodegenerative diseases (for example, amyotrophic lateral sclerosis; 54) or as a result of disrupting cellular protein degradation pathways u…”
BackgroundDayal, S., Sparks, A., Jacob, J., Allende-Vega, N., Lane, D. P., & Saville, M. K. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m805871200 · Cited by 199
Overcoming Drug Resistance by Enhancing Apoptosis of Tumor Cells
Gimenez-Bonafe, P., Tortosa, A., & Perez-Tomas, R. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166600 · Cited by 196
BCL-2 family regulation by the 20S proteasome inhibitor bortezomib
Fennell, D. A., Chacko, A., & Mutti, L. (2007) · Oncogene · doi:10.1038/sj.onc.1210744 · Cited by 157
“PUMA has been shown recently, however, to be upregulated in a p53-dependent manner in response to the proteasome inhibitor epoxomicin (epoxo) (Concannon et al., 2007).”
BackgroundTargeting of Nuclear Factor-κB and Proteasome by Dithiocarbamate Complexes with Metals
Cvek, B., & Dvořák, Z. (2007) · Current Pharmaceutical Design · doi:10.2174/138161207782110390 · Cited by 154
“Proteasome inhibitors also induce a prominent increase of p53 levels and p53-dependent form of apoptosis in cancer cells [333].”
BackgroundKieran, D., Woods, I., Villunger, A., Strasser, A., & Prehn, J. H. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707906105 · Cited by 129
Self-citationChen, S., Dai, Y., Pei, X.-Y., & Grant, S. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.01481-08 · Cited by 128
“It has also been reported that Puma-deficient cells are resistant to apoptosis induced by proteasome inhibitors (11).”
BackgroundTundo, G. R., Sbardella, D., Santoro, A. M., Coletta, A., Oddone, F., Grasso, G., Milardi, D., Lacal, P. M., Marini, S., Purrello, R., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107579 · Cited by 125
Proteasome inhibition suppresses essential immune functions of human CD4+ T cells
Berges, C., Haberstock, H., Fuchs, D., Miltz, M., Sadeghi, M., Opelz, G., Daniel, V., & Naujokat, C. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02761.x · Cited by 127
Profiling proteasome activity in tissue with fluorescent probes
Berkers, C. R., van Leeuwen, F. W. B., Groothuis, T. A., Peperzak, V., van Tilburg, E. W., Borst, J., Neefjes, J. J., & Ovaa, H. (2007) · Molecular Pharmaceutics · doi:10.1021/mp0700256 · Cited by 102
Tang, J., Yang, L., Chen, J., Li, Q., Zhu, L., Xu, Q., Huang, G., Zhang, Z., Xiang, Y., Du, L., et al. (2019) · 癌症:英文版 · doi:10.1186/s40880-019-0424-2 · Cited by 108
Fuchs, D., Berges, C., Opelz, G., Daniel, V., & Naujokat, C. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21405 · Cited by 92
Zhang, Y., Xing, D., & Liu, L. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-11-1109 · Cited by 97
“Previous studies have shown that PUMA was necessary and sufficient for ER stress-induced apoptosis and was also activated in cells subjected to proteasome inhibition (Reimertz et al., 2003; Concannon et al., 2007).”
BackgroundMirza-Aghazadeh-Attari, M., Darband, S. G., Kaviani, M., Mihanfar, A., Aghazadeh Attari, J., Yousefi, B., & Majidinia, M. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.07.005 · Cited by 76
The Ubiquitin-Proteasome System Is Indispensable for the Maintenance of Muscle Stem Cells
Kitajima, Y., Suzuki, N., Nunomiya, A., Osana, S., Yoshioka, K., Tashiro, Y., Takahashi, R., Ono, Y., Aoki, M., & Nagatomi, R. (2018) · Stem Cell Reports · doi:10.1016/j.stemcr.2018.10.009 · Cited by 75
“In addition, proteasome inhibition has been shown to induce apoptosis in several different cell types (Concannon et al., 2007; Ding et al., 2007; Pandit and Gartel, 2011).”
BackgroundEvaluation of the BH3-only Protein Puma as a Direct Bak Activator
Dai, H., Pang, Y.-P., Ramirez-Alvarado, M., & Kaufmann, S. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.505701 · Cited by 73
Efficacious proteasome/HDAC inhibitor combination therapy for primary effusion lymphoma
Bhatt, S., Ashlock, B. M., Toomey, N., Diaz, L. A., Mesri, E. A., Lossos, I. S., & Ramos, J. C. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64503 · Cited by 73
Proteasome Inhibitors Induce p53-Independent Apoptosis in Human Cancer Cells
Pandit, B., & Gartel, A. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.010 · Cited by 62
Rizzatti, E. G., Mora-Jensen, H. I., Weniger, M. A., Gibellini, F., Lee, E., Daibata, M., Lai, R. L., & Wiestner, A. U. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190801910912 · Cited by 66
“A third family member, PUMA has also been found to induce cell death in neuroblastoma cells exposed to proteasome inhibitors [16].”
BackgroundTargeting the Ubiquitin-Mediated Proteasome Degradation of p53 for Cancer Therapy
DeVine, T., & Dai, M. (2013) · Current Pharmaceutical Design · doi:10.2174/1381612811319180009 · Cited by 62
miR-503-5p confers drug resistance by targeting PUMA in colorectal carcinoma
Xu, K., Chen, G., Qiu, Y., Yuan, Z., Li, H., Yuan, X., Sun, J., Xu, J., Liang, X., & Yin, P. (2017) · Oncotarget · doi:10.18632/oncotarget.15559 · Cited by 60
Chirumbolo, S., & Bjørklund, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010165 · Cited by 56
Cathepsin L Mediates the Degradation of Novel APP C-Terminal Fragments
Wang, H., Sang, N., Zhang, C., Raghupathi, R., Tanzi, R. E., & Saunders, A. (2015) · Biochemistry · doi:10.1021/acs.biochem.5b00329 · Cited by 49
Concannon, C. G., Ward, M. W., Bonner, H. P., Kuroki, K., Tuffy, L. P., Bonner, C. T., Woods, I., Engel, T., Henshall, D. C., & Prehn, J. H. M. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05187.x · Cited by 52
Self-citationTargeting the ubiquitin–proteasome system to activate wild-type p53 for cancer therapy
Allende-Vega, N., & Saville, M. K. (2009) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2009.10.004 · Cited by 52
Hetschko, H., Voss, V., Seifert, V., Prehn, J. H. M., & Kögel, D. (2008) · FEBS Journal · doi:10.1111/j.1742-4658.2008.06351.x · Cited by 47
Self-citationActive-site directed probes to report enzymatic action in the ubiquitin proteasome system
Ovaa, H. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2128 · Cited by 51
“Increased p53 levels are normally observed upon proteasome inhibition and p53 (Ref”
BackgroundYoshida, K., Yamaguchi, K., Mizuno, A., Unno, Y., Asai, A., Sone, T., Yokosawa, H., Matsuda, A., Arisawa, M., & Shuto, S. (2009) · Organic & Biomolecular Chemistry · doi:10.1039/b900384c · Cited by 46
Autophagy is the predominant process induced by arsenite in human lymphoblastoid cell lines
Bolt, A. M., Byrd, R. M., & Klimecki, W. T. (2010) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2010.01.019 · Cited by 43
“In order to verify that LCL18564 is indeed capable of apoptosis, the AV/PI assay was used to evaluate cells exposed to epoxomicin, a proteasome inhibitor reported to induce apoptosis (Concannon et al., 2007).”
MethodLaussmann, M. A., Passante, E., Hellwig, C. T., Tomiczek, B., Flanagan, L., Prehn, J. H. M., Huber, H. J., & Rehm, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.304378 · Cited by 44
Self-citationCinnamaldehyde: Pharmacokinetics, anticancer properties and therapeutic potential (Review)
Han, R., Li, X., Gao, X., & Lv, G. (2024) · Molecular Medicine Reports · doi:10.3892/mmr.2024.13287 · Cited by 47
“The proteasome is an anticancer target, and proteasome inhibition can promote apoptosis and inhibit tumor growth (78,79).”
BackgroundThe Proteasome as a Drug Target in the Metazoan Pathogen, Schistosoma mansoni
Bibo‐Verdugo, B., Wang, S. C., Almaliti, J., Ta, A. P., Jiang, Z., Wong, D. A., Lietz, C. B., Suzuki, B. M., El‐Sakkary, N., HOOK, V. Y. H., et al. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00237 · Cited by 38
Telang (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000228 · Cited by 37
“These genes are also known to arrest the cells in the S phase and initiate apoptosis (19,20).”
Benaglio, P., Zhu, H., Okino, M.-L., Yan, J., Elgamal, R. M., Nariai, N., Beebe, E., Korgaonkar, K., Qiu, Y., Donovan, M. K. R., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100214 · Cited by 40
Hiss, D. C., & Gabriels, G. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903052559 · Cited by 37
“Further confirmation of the cooperation between p53 and the ERS-UPR in promoting cell survival or death has recently been demonstrated in human SH-SY5Y neuroblastoma cells exposed to epoxomicin, a selective inhibitor of the UPS, which not only resulted in the release of cytochrome c from mitochondria (an apoptotic sig…”
BackgroundInfluentialBaceridin, a Cyclic Hexapeptide from an Epiphytic Bacillus Strain, Inhibits the Proteasome
Niggemann, J., Bozko, P. M., Bruns, N., Wodtke, A., Gieseler, M. T., Thomas, K., Jahns, C., Nimtz, M., Reupke, I., Brüser, T., et al. (2014) · ChemBioChem · doi:10.1002/cbic.201300778 · Cited by 38
BAX/BAK–Independent Mitoptosis during Cell Death Induced by Proteasome Inhibition?
Lomonosova, E. E., Ryerse, J. S., & Chinnadurai, G. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0183 · Cited by 34
“In addition, several studies have shown that proteasome inhibition leads to apoptosis in various cancer cells (3-6).”
BackgroundThe Development and Pharmacology of Proteasome Inhibitors for the Management and Treatment of Cancer
Ruggeri, B., Miknyoczki, S. J., Dorsey, B. D., & Hui, A. (2009) · Advances in pharmacology · doi:10.1016/s1054-3589(08)57003-7 · Cited by 34
Köhler, B., Anguissola, S., Concannon, C. G., Rehm, M., Kögel, D., & Prehn, J. H. M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002844 · Cited by 36
“The measurement Annexin-V-FITC-staining of apoptotic cells was performed on a Cyflow ML16 flow cytometer (Partec, Munster, Germany) as described previously”
MethodSelf-citationBunk, E. C., König, H.-G., Bernaś, T., Engel, T., Henshall, D. C., Kirby, B. P., & Prehn, J. H. M. (2010) · Cell Death and Disease · doi:10.1038/cddis.2009.13 · Cited by 33
Self-citationKüçüksayan, E., Bozkurt, F., Yılmaz, M. T., Sırcan-Küçüksayan, A., Hanikoglu, A., & Özben, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-92447-x · Cited by 30
Fluorescence-Based Proteasome Activity Profiling
de Jong, A., Schuurman, K. G., Rodenko, B., Ovaa, H., & Berkers, C. R. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-364-6_13 · Cited by 29
Ferroptosis-associated genes and compounds in renal cell carcinoma
He, C., Li, Q., Wu, W., Liu, K., Li, X., Zheng, H., & Lai, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1473203 · Cited by 31
“The p53-upregulated modulator of apoptosis (PUMA) is a downstream target of p53 that mediates cell apoptosis (72).”
BackgroundAu, A. E., Sashindranath, M., Borg, R. J., Kleifeld, O., Andrews, R. K., Gardiner, E. E., Medcalf, R. L., & Samson, A. L. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.373 · Cited by 29
Boccellato, C., Kolbe, E., Peters, N., Jurić, V., Fullstone, G., Verreault, M., Idbaïh, A., Lamfers, M. L. M., Murphy, B. M., & Rehm, M. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03927-x · Cited by 28
“Cell death upon proteasome inhibition most prominently induces intrinsic apoptosis [34, 35], whereas death ligands primarily induce extrinsic apoptosis as the main cell death modality [36].”
BackgroundSelf-citationBonner, H. P., Concannon, C. G., Bonner, C., Woods, I., Ward, M. W., & Prehn, J. H. M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06790.x · Cited by 23
Self-citationQiang, W., Sui, F., Ma, J., Li, X., Ren, X., Shao, Y., Liu, J., Guan, H., Shi, B., & Hou, P. (2017) · Endocrine · doi:10.1007/s12020-017-1256-y · Cited by 24
Anti-cancer activities of cytokinin ribosides
Voller, J., Béreš, T., Zatloukal, M., Džubák, P., Hajdúch, M., Doležal, K., Schmülling, T., & Miroslav, S. (2019) · Phytochemistry Reviews · doi:10.1007/s11101-019-09620-4 · Cited by 24
“…Tosedostat (Krige et al. 2008), Elongation factor 1–alpha 1 inhibitor aplidin (Mitsiades et al. 2008) and proteasome inhibitor epoxomicin (Concannon et al. 2007)—induce gene profiles highly similar to iPR treatment, this similarity is largely driven by the genes that do not play a role…”
BackgroundBrancolini, C. (2008) · Current Molecular Pharmacology · doi:10.2174/1874-470210801010024 · Cited by 23
Gopalakrishnan, S., & Ismail, A. (2021) · Phytotherapy Research · doi:10.1002/ptr.7236 · Cited by 21
“Proteasome inhibition is known to promote apoptosis and leads to the suppression of tumor growth (Concannon et al., 2007).”
BackgroundDiallo, J.-S., Betton, B., Parent, N., Péant, B., Lessard, L., Page, C. L., Bertrand, R., Mes‐Masson, A., & Fred Saad, C. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604730 · Cited by 21
“…proapoptotic BH3-only proteins such as NOXA, BIK/NBK, BIM and PUMA see their levels increased following treatment with proteasome inhibitors such as MG-132, ALLN, lactacystin and bortezomib (Marshansky et al, 2001; Nikrad et al, 2005; Zhu et al, 2005; Qin et al, 2006; Concannon et al, 2007).”
BackgroundThe Toxic Effect of ALLN on Primary Rat Retinal Neurons
Li, N., Shang, L., Wang, S., Liao, L., Chen, D., Huang, J.-F., & Xiong, K. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9624-6 · Cited by 20
Tuffy, L. P., Concannon, C. G., D’Orsi, B., King, M. A., Woods, I., Huber, H. J., Ward, M. W., & Prehn, J. H. M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00575-10 · Cited by 20
“current with our previous results in human cancer cells (15), we identified Puma as a central mediator of proteasome inhibition-induced apoptosis.”
BackgroundResultSelf-citationTran, H. M., Wu, K.-S., Sung, S., Changou, C. A., Hsieh, T., Liu, Y., Liu, Y., Tsai, M., Lee, H., Hsieh, K. L., et al. (2020) · Cancers · doi:10.3390/cancers12030752 · Cited by 18
Franke, N. E., Kaspers, G. J. L., Assaraf, Y. G., van Meerloo, J., Niewerth, D., Kessler, F. L., Poddighe, P. J., Kole, J., Smeets, S. J., Ylstra, B., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.11340 · Cited by 18
King, M. A., Goemans, C. G., Hafiz, F., Prehn, J. H. M., Wyttenbach, A., & Tolkovsky, A. M. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.4751-08.2008 · Cited by 20
“Furthermore, consistent with induction of Hsp70, Bim, and c-Jun mRNA by proteasome inhibition (Butts et al., 2005; Yew et al., 2005; Concannon et al., 2007), we found an induction of their mRNAs (supplemental Fig.”
BackgroundSelf-citationTsuchiya, T., Bonner, H. P., Engel, T., Woods, I., Matsushima, S., Ward, M. W., Taki, W., Henshall, D. C., Concannon, C. G., & Prehn, J. H. M. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07538.x · Cited by 17
“RNA isolation, cDNA synthesis and real-time quantitative PCR Total RNA was isolated from OHSCs using the RNeasy kit from Qiagen (Crawley, UK).”
BackgroundMethodSelf-citationPatel, K. D., Zoysa, G. H. D., Kanamala, M., Patel, K., Pilkington, L. I., Barker, D. L. A., Reynisson, J., Wu, Z., & Sarojini, V. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01694 · Cited by 19
Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer
Boland, K., Flanagan, L., McCawley, N., Pabari, R. M., Kay, E. W., McNamara, D. A., Murray, F., Byrne, A. T., Ramtoola, Z., Concannon, C. G., et al. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.03.031 · Cited by 16
Self-citationTargeting Proteolysis with Cyanogenic Glycoside Amygdalin Induces Apoptosis in Breast Cancer Cells
Cecarini, V., Selmi, S., Cuccioloni, M., Gong, C., Bonfili, L., Zheng, Y., Cortese, M., Angeletti, M., Kilani, S., & Eleuteri, A. M. (2022) · Molecules · doi:10.3390/molecules27217591 · Cited by 15
Pipecolic esters as minimized templates for proteasome inhibition
Giletto, M. B., Osmulski, P. A., Jones, C. L., Gaczynska, M. E., & Tepe, J. J. (2019) · Organic & Biomolecular Chemistry · doi:10.1039/c9ob00122k · Cited by 14
dos Santos, P. W. D. S., Machado, A. R. T., Grandis, R. A. D., Ribeiro, D. L., Tuttis, K., Morselli, M., Aissa, A. F., Pellegrini, M. A., & Antunes, L. M. G. (2020) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2020.503201 · Cited by 13
Hiss, D. C., & Gabriels, G. A. (2009) · Expert Opinion on Drug Discovery · doi:10.1517/17460440903055032 · Cited by 13
“Epoxomicin, one of the earliest documented proteasome inhibitors that also exhibited evidence of in vivo anti-inflammatory activity [20,140], has recently been shown to activate the transcription of both PUMA (p53 upregulated modulator of apoptosis) and Bim in human colon cancer cells [137].”
BackgroundHuber, H. J., McKiernan, R. G., & Prehn, J. H. M. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1126-5 · Cited by 13
Self-citationTRAIL-induced apoptosis and proteasomal activity – Mechanisms, signalling and interplay
Boccellato, C., & Rehm, M. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2024.119688 · Cited by 14
Cheuka, P. M. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666210924101805 · Cited by 11
Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Cecarini, V., Cuccioloni, M., Mozzicafreddo, M., Bonfili, L., Angeletti, M., & Eleuteri, A. M. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794519815 · Cited by 10
“The accumulation of p53 triggers cellular responses that involve apoptosis, cell-cycle arrest, DNA repair, differentiation, and senescence [19, 20].”
BackgroundHainaut, P. L., Wiman, K. G., & Olivier, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8 · Cited by 10
The multifaceted role of PUMA in cell death pathways: its therapeutic potential across cancer types
Tat, S. S., Mandal, K., Sharma, T., Ghate, N. B., Barik, G. K., Gachhe, R. N., & Santra, M. K. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02112-3 · Cited by 10
“Epoxomicin enhances PUMA-mediated apoptosis, making it a promising option, particularly in p53-functional CRC [126].”
Wang, J., Wang, X., Zhang, L. G., Xie, S., Li, Z., Li, Y., Li, H. H., & Jiao, F. (2009) · Cytogenetic and Genome Research · doi:10.1159/000227831 · Cited by 10
“The intrinsic pathway is mediated by mitochondrial events, such as the release of apoptogenic proteins, the loss of mitochondrial transmembrane potential, m, and the production of reactive oxygen species, ROS [Burns and El-Deiry, 1999; Concannon et al., 2007].”
BackgroundRamapathiran, L., Bernaś, T., Walter, F., Williams, L. M., Düßmann, H., Concannon, C. G., & Prehn, J. H. M. (2013) · Journal of Cell Science · doi:10.1242/jcs.137158 · Cited by 7
“…has, in part, been attributed to the stabilisation of pro- apoptotic factors such as p53 (Lopes et al., 1997; MacLaren et al., 2001) and the induction and/or accumulation of BH3 proteins such as Puma (Concannon et al., 2007; Ding et al., 2007) and Noxa (Fernández et al., 2005; Qin et al., 2005).”
BackgroundSelf-citationSantamaría, E., Mora, M. I., Muñoz, J., Sánchez‐Quiles, V., Fernández‐Irigoyen, J., Prìeto, J., & Corrales, F. J. (2009) · PROTEOMICS · doi:10.1002/pmic.200900110 · Cited by 7
Individualized dynamic risk assessment and treatment selection for multiple myeloma
Murie, C., Turkarslan, S., Patel, A. P., Coffey, D. G., Becker, P. S., & Baliga, N. S. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-02987-6 · Cited by 6
Proteasome Stress Triggers Death of SH-SY5Y and T98G Cells via Different Cellular Mechanisms
Pilchová, I., Klacanova, K., Dibdiaková, K., Saksonova, S., Štefaniková, A., Vidomanová, E., Lichardusová, L., Hatok, J., & Račay, P. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2355-0 · Cited by 7
Larsson, P., Olsson, M., Sarathchandra, S., Beding, A. F., Forssell-Aronsson, E. B., Kovács, A., Karlsson, P., Helou, K., & Parris, T. Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-62339-x · Cited by 5
Zhou, X., Li, J., Marx, C., Tolstov, Y. L., Rauch, G., Herpel, E., Macher‐Goeppinger, S., Roth, W., Grüllich, C., Pahernik, S. A., et al. (2015) · Translational Oncology · doi:10.1016/j.tranon.2015.11.003 · Cited by 5
“Although the existence of PUMA-independent caspase activation and apoptosis induction has previously been reported in colon cancer cells as well as neuronal cells [15,16], the underlying mechanisms remain unclear.”
BackgroundPSMC5 insufficiency and P320R mutation impair proteasome function
Yu, Z.-Q., Carmichael, J., Collins, G. A., D'Agostino, M. D., Lessard, M., Firth, H. V., Harijan, P., Fry, A. E., Dean, J., Zhang, J., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae085 · Cited by 4
The proteasome as a drug target for treatment of parasitic diseases
Liu, L. J., O’Donoghue, A. J., & Caffrey, C. R. (2024) · Advances in Parasitology/Advances in parasitology · doi:10.1016/bs.apar.2024.04.001 · Cited by 4
Bradshaw, J. M., Nguyen, L., Wallace, W., Li, C., Sauer, J., Bard, F., & Bova, M. P. (2012) · Assay and Drug Development Technologies · doi:10.1089/adt.2011.398 · Cited by 4
“In addition to Pro-NGF, cells were also stimulated with control compounds known to be associated with apoptosis and caspase-3 activation; these compounds were the proteasome inhibitor epoxomicin and the nonspecific kinase inhibitor staurosporine.(25,26) A 76% increase in the caspase-3 activity over baseline was observ…”
Green Tea Extract Induces Apoptosis in the AGS Gastric Carcinoma Cell Line
Gonzàlez, F. (2014) · Natural Products Chemistry & Research · doi:10.4172/2329-6836.1000130 · Cited by 3
“Proteasome inhibition in AGS cells results in induction of apoptosis Proteasome inhibition is known to efficiently induce apoptosis in cultured cells [30-32].”
BackgroundProteasome Inhibition as a Novel Strategy for Cancer Treatment
Shen, M., & Dou, Q. P. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_12 · Cited by 3
Ellina, M.-I., Bouris, P., Kletsas, D., Aletras, A. J., & Karamanos, N. K. (2014) · ScienceOpen Research · doi:10.14293/a2199-1006.01.sor-life.ac0e6.v1 · Cited by 3
Hamidi, R., Ataei, F., & Hosseinkhani, S. (2022) · Medical Oncology · doi:10.1007/s12032-022-01716-w · Cited by 3
Ellina, M., Bouris, P., Kletsas, D., Aletras, A. J., & Karamanos, N. K. (2014) · ScienceOpen Research · doi:10.14293/s2199-1006.1.sor-life.aac0e6.v2 · Cited by 1
Characterization of the pro-apoptotic function of eIF5A in human cancer cell lines
Sun, Z. (2007) · UWSpace (University of Waterloo) · Cited by 1
Upstream Targets in the p53 Pathway
McCarthy, A. R., & Laín, S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3676-8_12
The Proteasome as a Therapeutic Target in Chronic Myeloid Leukemia
Pérez‐Roger, I., & Pilar, M. (2011) · InTech eBooks · doi:10.5772/27179
“Proteasome inhibitors block protein degradation, causing the accumulation of damaged proteins and inducing the heat shock response and cell death (Concannon et al., 2007; Friedman & Xue, 2004).”
BackgroundHarnessing Death Receptor Signaling for Cancer Treatment
Fulda, S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5847-0_11
Sharma, R. R., Bharti, O. C., & Kumar, D. (2007)
Manifestations of Drug Toxicity on Mitochondria in the Nervous System
Prehn, J. H. M., & Llorente‐Folch, I. (2018) · Wiley eBooks · doi:10.1002/9781119329725.ch9
Self-citationThe Proteasome as a Drug Target in Schistosoma mansoni
Wang, S. C. (2019) · eScholarship (California Digital Library)
THE ANTI-NEOPLASTIC ACTIVITY OF THE COORDINATIVE COMPOUNDS, THIOSEMICARBAZIDE DERIVATES
Pantea, V., & Lesnic, E. (2023) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.7830772
Liu, L. J. (2024) · eScholarship (California Digital Library)
CARM1 AS A POTENTIAL TARGET FOR INDUCING DIFFERENTIATION IN NEUROBLASTOMA
CANELLA, V. (2013) · Electronic Theses and Dissertations Repository (University of Pisa)
Yu, J., Xu, M. M., Wu, X., Kang, W.-B., Zou, W.-Y., Liu, Q., Zhang, D., & Yao, Y. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03664-7
“Among synergistically dysregulated pathways, apoptosis by epoxomicin (proteasome inhibitor) up [50] emerged as the most signi fi cantly enriched process, alongside pathways related to cell adhesion, AD, and glial cell function (Fig.”
Metadata
- Authors
- Concannon, C. G., Koehler, B. F., Reimertz, C., Murphy, B. M., Bonner, C., Thurow, N., Ward, M. W., Villunger, A., Strasser, A., Kögel, D., & Prehn, J. H. M.
- Affiliations
- Royal College of Surgeons in Ireland (IE)
- Goethe University Frankfurt (DE)
- Innsbruck Medical University (AT)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Prehn, J H M
- Venue
- Oncogene
- Published
- 2006-09-18
- Volume
- 26
- Issue
- 12
- Pages
- 1681-1692
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2056205420
- Cited by
- 95
- References
- 55
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 7 · 2022: 3 · 2021: 4 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 4 · 2016: 3 · 2015: 2 · 2014: 6 · 2013: 4 · 2012: 6
- FWCI
- 4.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Science Foundation Ireland
- Deutsche Forschungsgemeinschaft
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- proteasome inhibition, apoptosis, p53, PUMA, building information modeling, BH3-only proteins, epoxomicin, caspase activation, cytochrome c release, neuroblastoma, colon cancer, transcriptional regulation, antineoplastic therapy, p53-dependent apoptosis
- MeSH terms
- Base Sequence, Humans, Molecular Sequence Data, Proto-Oncogene Proteins, Tumor Suppressor Protein p53, Apoptosis, Protein Folding, DNA Primers, Oligonucleotide Array Sequence Analysis, Cell Line, Tumor, Apoptosis Regulatory Proteins, Proteasome Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.